90 related articles for article (PubMed ID: 37591293)
1. First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.
Özgüroğlu M; Kilickap S; Sezer A; Gümüş M; Bondarenko I; Gogishvili M; Nechaeva M; Schenker M; Cicin I; Ho GF; Kulyaba Y; Zyuhal K; Scheusan RI; Garassino MC; He X; Kaul M; Okoye E; Li Y; Li S; Pouliot JF; Seebach F; Lowy I; Gullo G; Rietschel P
Lancet Oncol; 2023 Sep; 24(9):989-1001. PubMed ID: 37591293
[TBL] [Abstract][Full Text] [Related]
2. First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial.
Zhong H; Sun S; Chen J; Wang Z; Zhao Y; Zhang G; Chen G; Zhou M; Zhou J; Du Y; Wu L; Xu Z; Mei X; Zhang W; He J; Cui J; Zhang Z; Luo H; Liu W; Sun M; Wu J; Shen Y; Zhang S; Yang N; Wang M; Lu J; Li K; Yao W; Sun Q; Yue H; Wang L; Ye S; Li B; Zhuang X; Pan Y; Zhang M; Shu Y; He Z; Pan L; Ling Y; Liu S; Zhang Q; Jiao S; Han B
Lancet Respir Med; 2024 May; 12(5):355-365. PubMed ID: 38309287
[TBL] [Abstract][Full Text] [Related]
3. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Janjigian YY; Shitara K; Moehler M; Garrido M; Salman P; Shen L; Wyrwicz L; Yamaguchi K; Skoczylas T; Campos Bragagnoli A; Liu T; Schenker M; Yanez P; Tehfe M; Kowalyszyn R; Karamouzis MV; Bruges R; Zander T; Pazo-Cid R; Hitre E; Feeney K; Cleary JM; Poulart V; Cullen D; Lei M; Xiao H; Kondo K; Li M; Ajani JA
Lancet; 2021 Jul; 398(10294):27-40. PubMed ID: 34102137
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial.
Kato K; Doki Y; Chau I; Xu J; Wyrwicz L; Motoyama S; Ogata T; Kawakami H; Hsu CH; Adenis A; El Hajbi F; Di Bartolomeo M; Braghiroli MI; Holtved E; Makino T; Blum Murphy M; Amaya-Chanaga C; Patel A; Hu N; Matsumura Y; Kitagawa Y; Ajani J
Cancer Med; 2024 May; 13(9):e7235. PubMed ID: 38716626
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study.
Diaz LA; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt C; Smith D; Garcia-Carbonero R; Benavides M; Gibbs P; de la Fourchardiere C; Rivera F; Elez E; Le DT; Yoshino T; Zhong WY; Fogelman D; Marinello P; Andre T;
Lancet Oncol; 2022 May; 23(5):659-670. PubMed ID: 35427471
[TBL] [Abstract][Full Text] [Related]
6. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial.
Baramidze A; Makharadze T; Gogishvili M; Melkadze T; Giorgadze D; Penkov K; Laktionov K; Nemsadze G; Nechaeva M; Rozhkova I; Kalinka E; Ag McIntyre D; Perez J; Kaul M; Quek RGW; Seebach F; Rietschel P; Pouliot JF
Lung Cancer; 2024 May; 193():107821. PubMed ID: 38820979
[TBL] [Abstract][Full Text] [Related]
7. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S; Chan SL; Gu S; Bai Y; Ren Z; Lin X; Chen Z; Jia W; Jin Y; Guo Y; Hu X; Meng Z; Liang J; Cheng Y; Xiong J; Ren H; Yang F; Li W; Chen Y; Zeng Y; Sultanbaev A; Pazgan-Simon M; Pisetska M; Melisi D; Ponomarenko D; Osypchuk Y; Sinielnikov I; Yang TS; Liang X; Chen C; Wang L; Cheng AL; Kaseb A; Vogel A;
Lancet; 2023 Sep; 402(10408):1133-1146. PubMed ID: 37499670
[TBL] [Abstract][Full Text] [Related]
8. Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study.
Leal T; Kotecha R; Ramlau R; Zhang L; Milanowski J; Cobo M; Roubec J; Petruzelka L; Havel L; Kalmadi S; Ward J; Andric Z; Berghmans T; Gerber DE; Kloecker G; Panikkar R; Aerts J; Delmonte A; Pless M; Greil R; Rolfo C; Akerley W; Eaton M; Iqbal M; Langer C;
Lancet Oncol; 2023 Sep; 24(9):1002-1017. PubMed ID: 37657460
[TBL] [Abstract][Full Text] [Related]
9. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.
Pal SK; Albiges L; Tomczak P; Suárez C; Voss MH; de Velasco G; Chahoud J; Mochalova A; Procopio G; Mahammedi H; Zengerling F; Kim C; Osawa T; Angel M; Gupta S; Khan O; Bergthold G; Liu B; Kalaitzidou M; Huseni M; Scheffold C; Powles T; Choueiri TK
Lancet; 2023 Jul; 402(10397):185-195. PubMed ID: 37290461
[TBL] [Abstract][Full Text] [Related]
10. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.
Gomez DR; Blumenschein GR; Lee JJ; Hernandez M; Ye R; Camidge DR; Doebele RC; Skoulidis F; Gaspar LE; Gibbons DL; Karam JA; Kavanagh BD; Tang C; Komaki R; Louie AV; Palma DA; Tsao AS; Sepesi B; William WN; Zhang J; Shi Q; Wang XS; Swisher SG; Heymach JV
Lancet Oncol; 2016 Dec; 17(12):1672-1682. PubMed ID: 27789196
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.
Marron TU; Fiel MI; Hamon P; Fiaschi N; Kim E; Ward SC; Zhao Z; Kim J; Kennedy P; Gunasekaran G; Tabrizian P; Doroshow D; Legg M; Hammad A; Magen A; Kamphorst AO; Shareef M; Gupta NT; Deering R; Wang W; Wang F; Thanigaimani P; Mani J; Troncoso L; Tabachnikova A; Chang C; Akturk G; Buckup M; Hamel S; Ioannou G; Hennequin C; Jamal H; Brown H; Bonaccorso A; Labow D; Sarpel U; Rosenbloom T; Sung MW; Kou B; Li S; Jankovic V; James N; Hamon SC; Cheung HK; Sims JS; Miller E; Bhardwaj N; Thurston G; Lowy I; Gnjatic S; Taouli B; Schwartz ME; Merad M
Lancet Gastroenterol Hepatol; 2022 Mar; 7(3):219-229. PubMed ID: 35065058
[TBL] [Abstract][Full Text] [Related]
12. Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.
Heymach JV; Harpole D; Mitsudomi T; Taube JM; Galffy G; Hochmair M; Winder T; Zukov R; Garbaos G; Gao S; Kuroda H; Ostoros G; Tran TV; You J; Lee KY; Antonuzzo L; Papai-Szekely Z; Akamatsu H; Biswas B; Spira A; Crawford J; Le HT; Aperghis M; Doherty GJ; Mann H; Fouad TM; Reck M;
N Engl J Med; 2023 Nov; 389(18):1672-1684. PubMed ID: 37870974
[TBL] [Abstract][Full Text] [Related]
13. Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II study.
Yang JJ; Huang C; Fan Y; Pan H; Feng J; Jiang L; Li XY; Liu XQ; Xiong JP; Zhao YQ; Cheng Y; Ma R; Wang J; Wang Y; Liu YH; Lin DM; Wang T; Shi W; Zou J; Wu YL
Cancer Immunol Immunother; 2022 Jun; 71(6):1393-1402. PubMed ID: 34668977
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab Plus Chemotherapy Per PD-L1 Stratum In Patients With Metastatic Non-Small Cell Lung Cancer: Real-World Effectiveness Versus Trial Efficacy.
Verschueren MV; Peters BJ; Bloem LT; Kruik VR; Uitvlugt EB; Bijsmans AR; Egberts AC; van de Garde EM
Clin Lung Cancer; 2024 Mar; 25(2):119-127.e1. PubMed ID: 38246791
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cells loaded with allogeneic tumour cell lysate plus best supportive care versus best supportive care alone in patients with pleural mesothelioma as maintenance therapy after chemotherapy (DENIM): a multicentre, open-label, randomised, phase 2/3 study.
Aerts JG; Belderbos R; Baas P; Scherpereel A; Bezemer K; Enninga I; Meijer R; Willemsen M; Berardi R; Fennell D; Kerstens R; Cornelissen R; van Meerbeeck JP;
Lancet Oncol; 2024 Jun; ():. PubMed ID: 38848742
[TBL] [Abstract][Full Text] [Related]
16. STAR-121: A Phase III Randomized Study of Domvanalimab and Zimberelimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Untreated Metastatic Non-Small Cell Lung Cancer With No Actionable Gene Alterations.
Rodriguez-Abreu D; Bosch-Barrera J; Gray JE; Ahn MJ; Johnson M; Yu X; Mohammad S; Chen X; Todd T; Kim J; Reck M
Clin Lung Cancer; 2024 May; 25(3):274-279. PubMed ID: 38310035
[TBL] [Abstract][Full Text] [Related]
17. Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.
Liu X; Zhang Y; Yang KY; Zhang N; Jin F; Zou GR; Zhu XD; Xie FY; Liang XY; Li WF; He ZY; Chen NY; Hu WH; Wu HJ; Shi M; Zhou GQ; Mao YP; Guo R; Sun R; Huang J; Liang SQ; Wu WL; Su Z; Li L; Ai P; He YX; Zang J; Chen L; Lin L; Huang SH; Xu C; Lv JW; Li YQ; Hong SB; Jie YS; Li H; Huang SW; Liang YL; Wang YQ; Peng YL; Zhu JH; Zang SB; Liu SR; Lin QG; Li HJ; Tian L; Liu LZ; Zhao HY; Lin AH; Li JB; Liu N; Tang LL; Chen YP; Sun Y; Ma J
Lancet; 2024 May; ():. PubMed ID: 38824941
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040.
El-Khoueiry AB; Trojan J; Meyer T; Yau T; Melero I; Kudo M; Hsu C; Kim TY; Choo SP; Kang YK; Yeo W; Chopra A; Soleymani S; Yao J; Neely J; Tschaika M; Welling TH; Sangro B
Ann Oncol; 2024 Apr; 35(4):381-391. PubMed ID: 38151184
[TBL] [Abstract][Full Text] [Related]
19. Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial.
; Fang W; Zhao Y; Luo Y; Yang R; Huang Y; He Z; Zhao H; Li M; Li K; Song Q; Du X; Sun Y; Li W; Xu F; Wang Z; Yang K; Fan Y; Liu B; Zhao H; Hu Y; Jia L; Xu S; Yi T; Lv D; Lan H; Li M; Liang W; Wang Y; Yang H; Jia Y; Chen Y; Lu J; Feng J; Liu C; Zhou M; Zhou J; Liu X; Zhou N; He M; Dong X; Chen H; Chen Y; Su H; Li X; Zhang Z; Yang L; Cheng Y; Chen L; Hou X; Zhang Y; Guo J; Wang Z; Lu H; Wu D; Feng W; Li W; Huang J; Wang Y; Song X; Peng J; Liu L; Guo Y; Li W; Lu D; Hu M; Wang ZM; Li B; Xia M; Zhang L
JAMA; 2024 May; ():. PubMed ID: 38820549
[TBL] [Abstract][Full Text] [Related]
20. Network meta-analysis of first-line systemic regimens for older patients with advanced NSCLC.
Luciani A; Dottorini L; Battaiotto E; Petrelli F
Anticancer Drugs; 2024 Jul; 35(6):576-583. PubMed ID: 38527420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
